Fatemeh Rahmatabadi

  • Fatemeh Sadat Heidari Rahmatabadi

    Fatemeh  Rahmatabadi

    ORCID:

  • Researcher ID:
  • Scopus:
  • Google Scholar:
  • Research Gate:

SCIENTIFIC CAREER

Since 2024

PhD Candidate C-MYC, Faculty of Medicine, University of Bergen, Norway

2022 – 2024 Master Student at Master in Biomedical Sciences, Faculty of Medicine, University of Bergen, Norway

2017 – 2021 Bachelor of Science in Cell and Molecular Biology, Islamic Azad University of Mashhad, Mashhad, Iran

COURSE

  1. First Steps with R in Life Sciences, 13-14 October 2025, Lausanne, Switzerland 

POSTER presentations

  1. Fatemeh Sadat Heidari Rahmatabadi, Tuyen Hoang, Vibeke Andresen, Gro Gausdal, Simona Chera, Bjørn Tore Gjertsen, Luiza Ghila. Targeting MAPK/ERK Signaling Pathway to Overcome Chemotherapy Resistance in Acute Myeloid Leukemia, c-myc Single Cell Satellite Seminar, 12 May 2025, Solstrand, Norway
  2. Fatemeh Sadat Heidari Rahmatabadi, Tuyen Hoang, Vibeke Andresen, Gro Gausdal, Simona Chera, Bjørn Tore Gjertsen, Luiza Ghila. Targeting MAPK/ERK Signaling Pathway to Overcome Chemotherapy Resistance in Acute Myeloid Leukemia, CCBIO’s 13th Annual Symposium, 13-14 May 2025, Solstrand, Norway

Journal Club Posts

  1. RSK1 dependency in FLT3-ITD acute myeloid leukemia
  2. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
  3. ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease
  4. The p38 pathway inhibitor, SB202190, activates MEK/MAPK to stimulate the growth of leukemia cells
  5. Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation
  6. Pharmacology and toxicology of the novel investigational agent Cantrixil